Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 7/20 | 0.70 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | NEK2 | P51955 | 2/20 | 0.49 |
| ▸ | GAK | O14976 | 2/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.42 |
| ▸ | STK17B | O94768 | 1/20 | 0.41 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5475989 | 0.91 | NOS1 (0.65) | NOS1PI4KBPDE4APDE4BPDE4C | |
| SCHEMBL5464730 | 0.90 | NOS1 (0.69) | NOS1PI4KBPDE4APDE4BPDE4C | |
| SCHEMBL4551815 | 0.90 | NOS1 (0.77) | NOS1PI4KBPDE4APDE4BPDE4C | |
| SCHEMBL5461351 | 0.90 | NOS1 (0.68) | NOS1PI4KBPDE4APDE4BPDE4C | |
| SCHEMBL5469937 | 0.89 | NOS1 (0.75) | NOS1PI4KBPDE4APDE4BPDE4C | |
| SCHEMBL5475844 | 0.89 | NOS1 (0.62) | NOS1PI4KBPDE4APDE4BPDE4C | |
| SCHEMBL5469817 | 0.88 | NOS1 (0.79) | NOS1PI4KBPDE4APDE4BPDE4C | |
| SCHEMBL5471634 | 0.87 | NOS1 (0.64) | NOS1PI4KBPDE4APDE4BPDE4C | |
| SCHEMBL5458990 | 0.87 | NOS1 (0.64) | NOS1PI4KBPDE4APDE4BPDE4C | |
| SCHEMBL5461838 | 0.86 | NOS1 (0.68) | NOS1PI4KBPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1673092-B1 | HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY | 4 AZA IP NV (BE) | 2007-08-15 | — | — | EP | claimed |
| US-20070032477-A1 | Pteridine derivatives useful for making pharmaceutical compositions | 4 AZA BIOSCIENCE NV (BE) | 2007-02-08 | — | — | US | claimed |
| EP-1673092-B1 | HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY | 4 AZA IP NV (BE) | 2007-08-15 | — | — | EP | disclosed |
| US-20070032477-A1 | Pteridine derivatives useful for making pharmaceutical compositions | 4 AZA BIOSCIENCE NV (BE) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032477-A1 | Pteridine derivatives useful for making pharmaceutical compositions | TPMT, TYMS, TNF | NOS1 107/4885PI4KB 2052/4885PDE4A 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.